Hydroquinone is often considered one of the strongest and most effective tools available for treating hyperpigmentation. However, it is also surrounded by a fair share of misconceptions that can cause hesitation for patients.

‍

In this Next Steps in Derm video interview, conducted in conjunction with the Pigmentary Disorders Exchange Symposium, Rebecca Vasquez, MD, FAAD, addresses concerns over malignancy risk and exogenous ochronosis. She emphasizes that exogenous ochronosis is rare in regulated settings due to careful protocols, including prescription-level control, treatment cycling, and recognition of early warning signs.

‍

Dr. Vasquez, associate professor in the Department of Dermatology at UT Southwestern Medical Center, shares her personal experience in addressing safety concerns with patients. She finds that discussing the actual risks versus benefits often leads to increased patient comfort as they understand severe side effects rarely happen under proper medical supervision. She encourages open conversations with patients and setting realistic expectations when treating pigmentary conditions with hydroquinone.